A detailed history of Charles Schwab Investment Management Inc transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 431,897 shares of PCRX stock, worth $7.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
431,897
Previous 415,078 4.05%
Holding current value
$7.3 Million
Previous $11.9 Million 45.23%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$11.7 - $28.46 $196,782 - $478,668
16,819 Added 4.05%
431,897 $6.5 Million
Q2 2024

Aug 12, 2024

BUY
$25.5 - $31.51 $23,638 - $29,209
927 Added 0.22%
415,078 $11.9 Million
Q1 2024

May 08, 2024

BUY
$27.7 - $35.48 $1.18 Million - $1.51 Million
42,485 Added 11.43%
414,151 $12.1 Million
Q4 2023

Feb 06, 2024

BUY
$26.32 - $34.31 $307,838 - $401,289
11,696 Added 3.25%
371,666 $12.5 Million
Q3 2023

Nov 08, 2023

BUY
$30.68 - $40.09 $351,378 - $459,150
11,453 Added 3.29%
359,970 $11 Million
Q2 2023

Aug 09, 2023

BUY
$36.12 - $47.5 $22,863 - $30,067
633 Added 0.18%
348,517 $14 Million
Q1 2023

May 11, 2023

BUY
$35.53 - $43.38 $244,446 - $298,454
6,880 Added 2.02%
347,884 $14.2 Million
Q4 2022

Feb 13, 2023

BUY
$38.19 - $57.45 $352,455 - $530,206
9,229 Added 2.78%
341,004 $13.2 Million
Q3 2022

Nov 14, 2022

BUY
$51.24 - $58.89 $544,783 - $626,118
10,632 Added 3.31%
331,775 $17.6 Million
Q2 2022

Aug 15, 2022

SELL
$51.49 - $81.64 $1.43 Million - $2.26 Million
-27,705 Reduced 7.94%
321,143 $18.7 Million
Q1 2022

May 13, 2022

SELL
$60.03 - $76.49 $643,521 - $819,972
-10,720 Reduced 2.98%
348,848 $26.6 Million
Q4 2021

Feb 11, 2022

BUY
$47.97 - $62.21 $887,828 - $1.15 Million
18,508 Added 5.43%
359,568 $21.6 Million
Q3 2021

Nov 16, 2021

BUY
$54.64 - $61.3 $1.07 Million - $1.2 Million
19,642 Added 6.11%
341,060 $19.1 Million
Q2 2021

Aug 16, 2021

BUY
$59.18 - $69.99 $343,835 - $406,641
5,810 Added 1.84%
321,418 $19.5 Million
Q1 2021

May 17, 2021

SELL
$59.31 - $78.82 $1.21 Million - $1.6 Million
-20,321 Reduced 6.05%
315,608 $22.1 Million
Q4 2020

Feb 16, 2021

BUY
$50.47 - $66.26 $163,270 - $214,351
3,235 Added 0.97%
335,929 $20.1 Million
Q3 2020

Nov 13, 2020

SELL
$51.97 - $63.0 $1.11 Million - $1.35 Million
-21,389 Reduced 6.04%
332,694 $20 Million
Q2 2020

Aug 14, 2020

BUY
$30.8 - $52.47 $412,412 - $702,573
13,390 Added 3.93%
354,083 $18.6 Million
Q1 2020

May 15, 2020

BUY
$28.4 - $50.7 $138,137 - $246,604
4,864 Added 1.45%
340,693 $11.4 Million
Q4 2019

Feb 07, 2020

BUY
$36.31 - $46.83 $283,254 - $365,320
7,801 Added 2.38%
335,829 $15.2 Million
Q3 2019

Nov 08, 2019

BUY
$35.66 - $44.99 $1.06 Million - $1.34 Million
29,699 Added 9.96%
328,028 $12.5 Million
Q2 2019

Aug 09, 2019

BUY
$36.57 - $47.97 $371,295 - $487,039
10,153 Added 3.52%
298,329 $13 Million
Q1 2019

May 14, 2019

BUY
$36.47 - $42.17 $1.12 Million - $1.3 Million
30,783 Added 11.96%
288,176 $11 Million
Q4 2018

Feb 14, 2019

BUY
$41.31 - $52.16 $687,357 - $867,890
16,639 Added 6.91%
257,393 $11.1 Million
Q3 2018

Nov 13, 2018

BUY
$32.85 - $52.0 $904,360 - $1.43 Million
27,530 Added 12.91%
240,754 $11.8 Million
Q2 2018

Aug 08, 2018

BUY
$27.5 - $39.8 $493,625 - $714,410
17,950 Added 9.19%
213,224 $6.83 Million
Q1 2018

May 07, 2018

BUY
$29.98 - $46.35 $240,589 - $371,958
8,025 Added 4.29%
195,274 $6.08 Million
Q4 2017

Jan 17, 2018

SELL
$31.85 - $46.95 $45,481 - $67,044
-1,428 Reduced 0.76%
187,249 $8.55 Million
Q3 2017

Nov 13, 2017

BUY
$35.7 - $39.5 $6.74 Million - $7.45 Million
188,677
188,677 $7.09 Million

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $775M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.